Page 1515 - Williams Hematology ( PDFDrive )

1490 Part X: Malignant Myeloid Diseases <CN>: <CT> PB

1014. Martiat P, Michaux JL, Rodhain J, et al: Philadelphia-negative (Ph−) chronic myeloid 1025. Chee YL, Vickers MA, Stevenson D, et al: Fatal myelodysplastic syndrome develop-
leukemia (CML): Comparison with Ph+ CML and chronic myelomonocytic leuke- ing during therapy with imatinib mesylate and characterized by the emergence of
mia. Blood 78:205, 1991. complex Philadelphia negative clones. Leukemia 17:634, 2003.
1015. van der Plas DC, Grosveld G, Hagemeijer A: Review of clinical, cytogenetic, and 1026. Meeus P, Demuynck H, Martiat P, et al: Sustained clonal karyotype abnormalities in
molecular aspects of Ph-negative CML. Cancer Genet Cytogenet 52:143, 1991. the Philadelphia chromosome negative cells of CML patients successfully treated with
1016. Galton DA: Haematological differences between chronic granulocytic leukemia, imatinib. Leukemia 17:465, 2003.
atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia. Leuk 1027. Bumm T, Muller C, Al Ali HK, et al: Emergence of clonal cytogenetic abnormalities in
Lymphoma 7:343, 1992. Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of
1017. Kato Y, Sawada H, Tashima M et al: Heterogeneous features of Ph-negative CML— polyclonal hematopoiesis in the majority. Blood 101:1941, 2001.
Possible existence of Ph-negative, bcr-rearrangement-negative CML. Acta Haematol 1028. Galton DA: Haematological differences between chronic granulocytic leukaemia,
52:1004, 1989. atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia. Leuk
1018. Selleri L, Emilia G, Luppi M, et al: Chronic myelogenous leukemia with typical clin- Lymphoma 7:343, 1992.
ical and morphological features can be Philadelphia chromosome negative and “bcr 1029. Breccia M, Biondo F, Latagliata R, et al: Identification of risk factors in atypical
negative.” Hematol Pathol 4:67, 1990. chronic myeloid leukemia. Haematologica 91:1566, 2006.
1019. Costello R, Sainty D, Lafage-Pochitaloff M, Gabert J: Clinical and biological aspects 1030. Dinardo CD, Daver N, Jain N, et al: Myelodysplastic/myeloproliferative neoplasms,
of Philadelphia-negative/BCR-negative chronic myeloid leukemia. Leuk Lymphoma unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment
25:225, 1997. strategy. Leukemia 28:958, 2014.
1020. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al: BCR rearrangement-negative 1031. Wang SA, Hasserjian RP, Fox PS, et al: Atypical chronic myeloid leukemia is clinically
chronic myelogenous leukemia revisited. J Clin Oncol 19:2915, 2001. distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 123:
1021. Onida F, Ball G, Kantarjian HM, et al: Characteristics and outcome of patients with 2645, 2014.
Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. 1032. Meggendorfer M, Roller A, Haferlach T, et al: SRSF2 mutations in 275 cases with
Cancer 95:1673, 2002. chronic myelomonocytic leukemia (CMML). Blood 120:3080, 2012.
1022. O’Brien SG, Viera SA, Connors S, et al: Transient response to imatinib mesylate 1033. Sakaguchi H(1), Okuno Y, Muramatsu H, et al: Exome sequencing identifies second-
(STI571) in a patient with ETV6-ABL t(9;12) translocation. Blood 99:3465, 2002. ary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet
1023. Mauro MJ, Loriaux M, Deininger MW: Ph-positive and -negative myeloproliferative 45:937, 2013.
syndromes may coexist. Leukemia 18:1305, 2004.
1024. Raskind WH, Ferraris AM, Najfeld V, et al: Further evidence for the existence of a
clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia.
Leukemia 18:1305, 2004.

Kaushansky_chapter 89_p1437-1490.indd 1490 9/18/15 3:42 PM